NanoCept
Commercial- Indications
- Bacterial contamination prevention in orthopaedic implants
Company intelligence / Profile preview
Onkos Surgical has commercialized a portfolio of innovative solutions for complex musculoskeletal oncology and orthopaedic reconstruction. The company recently achieved the first FDA De Novo approval for an antibacterial coating on tumor and revision orthopaedic implants. Initial human cases using the NanoCept technology have been completed successfully. While robust preclinical data support efficacy against bacterial contamination, clinical effectiveness in reducing infection rates remains under evaluation. The company’s products are used by over 350 leading academic medical institutions in the US.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Onkos Surgical.